Home > Press > Nanoparticle Breast Cancer Drug O.K.D by FDA
"The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel."
Nanoparticle Breast Cancer Drug O.K.D by Food and Drug Administration
March 10, 2005
Research at Northwestern University Feinberg School of Medicine played a significant role in Food and Drug Administration approval of AbraxaneTM (paclitaxel protein-bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.
“The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel,” said principal clinical study investigator William J. Gradishar, M.D., associate professor of medicine, division of hematology/oncology at Feinberg and co-director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital.
Gradishar is also a breast cancer researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
“In our research, participants who no longer responded to some of the more common treatments showed improvement with Abraxane and experienced less-severe side effects that made treatment more tolerable,” Gradishar said.
Abraxane is engineered using a proprietary process (protein-bound nanoparticle technology) to create tiny particles (nanoparticles 100th the size of a red blood cell) in which the active chemotherapeutic drug, paclitaxel, is bound to a naturally occurring protein called albumin.
By using this nanotechnology, the active component (paclitaxel) can be delivered into the body at a 50 percent higher dose over 30 minutes.
This contrasts with Taxol, in which paclitaxel is dissolved in a toxic solvent, which requires pre-medication with steroids and antihistamines to avoid hypersensitivity reactions and must be given in infusions for up to three hours.
Because Abraxane is solvent-free, solvent-related toxicities are eliminated and premedication is not required.
In the clinical studies, the response rate for all participants treated with Abraxane was almost twice that of participants receiving the solvent-based paclitaxel injection. Without toxic solvents, Abraxane could be given at higher doses than Taxol, which may account, in part, for the increased anti-tumor activity.
In addition, albumin is a protein that normally transports nutrients to cells and has been shown to accumulate in rapidly growing tumors. Therefore, Abraxane’s increased effectiveness may also be due to preferential delivery of albumin-bound paclitaxel to cancer cells.
Abraxane was developed by American Bioscience and will be marketed by Abraxis Oncology, a division of American Pharmaceutical Partners.
Copyright © Northwestern University
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Lifeboat publishes its first book: The Lifeboat Foundation has published its first book, "The Human Race to the Future: What Could Happen -- and What to Do" May 14th, 2013
UC Santa Barbara History Professor's Book Elucidates, Celebrates ‘Visioneers' May 14th, 2013
Conceptual Nanomedical Lipofuscin Removal Strategy April 29th, 2013
The Global Desalination Market 2013-2023 April 24th, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013